ArticleInternational journal of microbiology2026
Evaluation of Xpert MTB/XDR and Deeplex Myc-TB for the Rapid Detection of Drug Resistance in
Article in International journal of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current Landscape of Molecular Diagnostic Tests and Emerging Tools for Tuberculosis and Drug Resistance.Diagnostics (Basel, Switzerland) · 2026Review
- Heteroresistance inFrontiers in cellular and infection microbiology · 2026Review
- Evaluation of Xpert MTB/XDR and Deeplex Myc-TB for the Rapid Detection of Drug Resistance inInternational journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rapid identification of drug-resistant tuberculosis remains critical for the initiation of appropriate treatment regimens, improved success rates and reduction in the development of drug resistance. In this study, we compared the diagnostic performance of two novel diagnostic tests, Xpert MTB/XDR and Deeplex Myc-TB (both CE marked). Methods: Twenty clinical isolates of Results: Xpert MTB/XDR had a total concordance of 68% and Deeplex Myc-TB had a total concordance of 100% when compared to WGS and phenotypic drug susceptibility testing. Xpert TB/XDR had a lower limit of detection for identifying MTB at 10^3 CFU/mL, whereas Deeplex Myc-TB required at least 10^4 CFU/mL. Both Xpert MTB/XDR and Deeplex Myc-TB were able to detect the wild type MTB without any cross-reactivity with the drug-resistant Mab. For heteroresistance detection, Deeplex Myc-TB was able to detect down to 1% admix of the resistant isolates (1 out of 4), whilst Xpert MTB/XDR was only able to detect down to 10% in 1 out of 4 mixtures of isolates tested. Conclusion: Both platforms represent an attractive option for the rapid detection of drug resistance and heteroresistance contributing to the management of complex cases, but further studies are needed to assess their real clinical impact.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.